Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine how effective Whipple at the Splenic Artery (WATSA).
Primary
The primary objective of this registry study is to collect clinical data from patients who undergo the WATSA procedure. Specific hypotheses to be tested are
Secondary
The secondary objectives of this registry study are to
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Whipple Surgery at the Splenic Artery | Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Whipple at the Splenic Artery (WATSA) | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effectivity of the Whipple at the Splenic Artery | To determine how effective Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins. | By CT scan at 8 weeks post surgery |
| To determine range of morbidity and mortality | To determine if Whipple at the splenic artery can be performed within the usual range of morbidity and mortality (30 day postoperative mortality) for a standard a Whipple procedure. | 30 day postoperative mortality |
| Measure | Description | Time Frame |
|---|---|---|
| Survival/recurrence at 2 years | To determine the survival/recurrence rates at 2 years. | 2 years |
| Effect of occlusion of the splenic vein at the confluence. | To determine the effect of occlusion of the splenic vein at the confluence. |
Not provided
Eligibility Criteria - Prospective Portion:
Eligibility Criteria - Retrospective Portion:
Patient underwent WATSA procedure at our institution between 01/01/2009 and 12/31/2011.
Not provided
Not provided
Participants will be identified from PI's patient population or referrals from colleagues.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven Strasberg, M.D. | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
Not provided
| Label | URL |
|---|---|
| Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| By CT scan at 8 weeks |
| D004066 |
| Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |